Subpleural fibrotic interstitial lung abnormalities are implicated in non-small cell lung cancer radiotherapy outcomes

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. doi: 10.3322/caac.21492 BrayF FerlayJ SoerjomataramI SiegelRL TorreLA JemalA Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2018 68 394 424 10.3322/caac.21492 Open DOISearch in Google Scholar

2. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 2019; 94: 1623–40. doi: 10.1016/j.mayocp.2019.01.013 DumaN Santana-DavilaR MolinaJR Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment Mayo Clin Proc 2019 94 1623 40 10.1016/j.mayocp.2019.01.013 Open DOISearch in Google Scholar

3. Brown S, Banfill K, Aznar MC, Whitehurst P, Faivre Finn C. The evolving role of radiotherapy in non-small cell lung cancer. Br J Radiol 2019; 92: 20190524. doi: 10.1259/bjr.20190524 BrownS BanfillK AznarMC WhitehurstP Faivre FinnC The evolving role of radiotherapy in non-small cell lung cancer Br J Radiol 2019 92 20190524 10.1259/bjr.20190524 Open DOISearch in Google Scholar

4. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022; 40: 1301–11. doi: 10.1200/JCO.21.01308 SpigelDR Faivre-FinnC GrayJE VicenteD PlanchardD Paz-AresL Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer J Clin Oncol 2022 40 1301 11 10.1200/JCO.21.01308 Open DOISearch in Google Scholar

5. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377: 1919–29. doi: 10.1056/NEJMoa1709937 AntoniaSJ VillegasA DanielD VicenteD MurakamiS HuiR Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer N Engl J Med 2017 377 1919 29 10.1056/NEJMoa1709937 Open DOISearch in Google Scholar

6. Inoue A, Kunitoh H, Sekine I, Sumi M, Tokuuye K, Saijo N. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 2001; 49: 649–55. doi: 10.1016/s0360-3016(00)00783-5 InoueA KunitohH SekineI SumiM TokuuyeK SaijoN Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis Int J Radiat Oncol Biol Phys 2001 49 649 55 10.1016/s0360-3016(00)00783-5 Open DOISearch in Google Scholar

7. Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, Muñoz-Montaño W, Nuñez-Baez M, Arrieta O. Radiation-induced lung injury: current evidence. BMC Pulm Med 2021; 21: 9. doi: 10.1186/s12890-020-01376-4 Arroyo-HernándezM MaldonadoF Lozano-RuizF Muñoz-MontañoW Nuñez-BaezM ArrietaO Radiation-induced lung injury: current evidence BMC Pulm Med 2021 21 9 10.1186/s12890-020-01376-4 Open DOISearch in Google Scholar

8. Hagiwara Y, Nakayama Y, Kudo S, Hayakawa T, Nakamura N, Kitamoto Y, et al. Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease. J Radiat Res 2020; 61: 563–74. doi: 10.1093/jrr/rraa018 HagiwaraY NakayamaY KudoS HayakawaT NakamuraN KitamotoY Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease J Radiat Res 2020 61 563 74 10.1093/jrr/rraa018 Open DOISearch in Google Scholar

9. Kashihara T, Nakayama Y, Ito K, Kubo Y, Okuma K, Shima S, et al. Usefulness of simple original interstitial lung abnormality scores for predicting radiation pneumonitis requiring steroidal treatment after definitive radiation therapy for patients with locally advanced non-small cell lung cancer. Adv Radiat Oncol 2021; 6: 100606. doi: 10.1016/j.adro.2020.10.019 KashiharaT NakayamaY ItoK KuboY OkumaK ShimaS Usefulness of simple original interstitial lung abnormality scores for predicting radiation pneumonitis requiring steroidal treatment after definitive radiation therapy for patients with locally advanced non-small cell lung cancer Adv Radiat Oncol 2021 6 100606 10.1016/j.adro.2020.10.019 Open DOISearch in Google Scholar

10. Higo H, Kubo T, Makimoto S, Makimoto G, Ihara H, Masaoka Y, et al. Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. Jpn J Clin Oncol 2019; 49: 458–64. doi: 10.1093/jjco/hyz016 HigoH KuboT MakimotoS MakimotoG IharaH MasaokaY Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities Jpn J Clin Oncol 2019 49 458 64 10.1093/jjco/hyz016 Open DOISearch in Google Scholar

11. Washko GR, Lynch DA, Matsuoka S, Ross JC, Umeoka S, Diaz A, et al. Identification of early interstitial lung disease in smokers from the COPDGene Study. Acad Radiol 2010; 17: 48–53. doi: 10.1016/j.acra.2009.07.016 WashkoGR LynchDA MatsuokaS RossJC UmeokaS DiazA Identification of early interstitial lung disease in smokers from the COPDGene Study Acad Radiol 2010 17 48 53 10.1016/j.acra.2009.07.016 Open DOISearch in Google Scholar

12. Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, et al. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med 2020; 8: 726–37. doi: 10.1016/S2213-2600(20)30168-5 HatabuH HunninghakeGM RicheldiL BrownKK WellsAU Remy-JardinM Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society Lancet Respir Med 2020 8 726 37 10.1016/S2213-2600(20)30168-5 Open DOISearch in Google Scholar

13. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452–8. doi: 10.1038/bmt.2012.244 KandaY Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics Bone Marrow Transplant 2013 48 452 8 10.1038/bmt.2012.244 Open DOISearch in Google Scholar

14. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 2007; 96: 644–7. doi: 10.1111/j.1651-2227.2006.00178.x AkobengAK Understanding diagnostic tests 3: receiver operating characteristic curves Acta Paediatr 2007 96 644 7 10.1111/j.1651-2227.2006.00178.x Open DOISearch in Google Scholar

15. Li F, Zhou Z, Wu A, Cai Y, Wu H, Chen M, et al. Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy. Radiat Oncol 2018; 13: 82. doi: 10.1186/s13014-018-1030-1 LiF ZhouZ WuA CaiY WuH ChenM Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy Radiat Oncol 2018 13 82 10.1186/s13014-018-1030-1 Open DOISearch in Google Scholar

16. Kobayashi H, Wakuda K, Naito T, Mamesaya N, Omori S, Ono A, et al. Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities. Radiat Oncol 2021; 16: 52. doi: 10.1186/s13014-021-01780-y KobayashiH WakudaK NaitoT MamesayaN OmoriS OnoA Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities Radiat Oncol 2021 16 52 10.1186/s13014-021-01780-y Open DOISearch in Google Scholar

17. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 2011; 364: 897–906. doi: 10.1056/NEJMoa1007285 WashkoGR HunninghakeGM FernandezIE NishinoM OkajimaY YamashiroT Lung volumes and emphysema in smokers with interstitial lung abnormalities N Engl J Med 2011 364 897 906 10.1056/NEJMoa1007285 Open DOISearch in Google Scholar

18. Chua F, Desai SR, Nicholson AG, Devaraj A, Renzoni E, Rice A, et al. Pleuroparenchymal fibroelastosis. A review of clinical, radiological, and pathological characteristics. Ann Am Thorac Soc 2019; 16: 1351–59. doi: 10.1513/AnnalsATS.201902-181CME ChuaF DesaiSR NicholsonAG DevarajA RenzoniE RiceA Pleuroparenchymal fibroelastosis. A review of clinical, radiological, and pathological characteristics Ann Am Thorac Soc 2019 16 1351 59 10.1513/AnnalsATS.201902-181CME Open DOISearch in Google Scholar

19. Oshiro Y, Mizumoto M, Sekino Y, Maruo K, Ishida T, Sumiya T, et al. Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: multi-institutional research in Japan. Clin Transl Radiat Oncol 2021; 29: 54–59. doi: 10.1016/j.ctro.2021.05.009 OshiroY MizumotoM SekinoY MaruoK IshidaT SumiyaT Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: multi-institutional research in Japan Clin Transl Radiat Oncol 2021 29 54 59 10.1016/j.ctro.2021.05.009 Open DOISearch in Google Scholar

20. Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2013; 85: 444–50. doi: 10.1016/j.ijrobp.2012.04.043 PalmaDA SenanS TsujinoK BarrigerRB RenganR MorenoM Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis Int J Radiat Oncol Biol Phys 2013 85 444 50 10.1016/j.ijrobp.2012.04.043 Open DOISearch in Google Scholar

21. Ito M, Shimizu H, Aoyama T, Tachibana H, Tomita N, Makita C, et al. Efficacy of virtual block objects in reducing the lung dose in helical tomotherapy planning for cervical oesophageal cancer: a planning study. Radiat Oncol 2018; 13: 62. doi: 10.1186/s13014-018-1012-3 ItoM ShimizuH AoyamaT TachibanaH TomitaN MakitaC Efficacy of virtual block objects in reducing the lung dose in helical tomotherapy planning for cervical oesophageal cancer: a planning study Radiat Oncol 2018 13 62 10.1186/s13014-018-1012-3 Open DOISearch in Google Scholar

22. Wu WC, Chan CL, Wong YW, Cuijpers JP. A study on the influence of breathing phases in intensity-modulated radiotherapy of lung tumours using four-dimensional CT. Br J Radiol 2010; 83: 252–6. doi: 10.1259/bjr/33094251 WuWC ChanCL WongYW CuijpersJP A study on the influence of breathing phases in intensity-modulated radiotherapy of lung tumours using four-dimensional CT Br J Radiol 2010 83 252 6 10.1259/bjr/33094251 Open DOISearch in Google Scholar

23. Putman RK, Gudmundsson G, Axelsson GT, Hida T, Honda O, Araki T, et al. Imaging patterns are associated with interstitial lung abnormality progression and mortality. Am J Respir Crit Care Med 2019; 200: 175–83. doi: 10.1164/rccm.201809-1652OC PutmanRK GudmundssonG AxelssonGT HidaT HondaO ArakiT Imaging patterns are associated with interstitial lung abnormality progression and mortality Am J Respir Crit Care Med 2019 200 175 83 10.1164/rccm.201809-1652OC Open DOISearch in Google Scholar

24. Iwasawa T, Okudela K, Takemura T, Fukuda T, Matsushita S, Baba T, et al. Computer-aided quantification of pulmonary fibrosis in patients with lung cancer: Relationship to disease-free survival. Radiology 2019; 292: 489–98. doi: 10.1148/radiol.2019182466 IwasawaT OkudelaK TakemuraT FukudaT MatsushitaS BabaT Computer-aided quantification of pulmonary fibrosis in patients with lung cancer: Relationship to disease-free survival Radiology 2019 292 489 98 10.1148/radiol.2019182466 Open DOISearch in Google Scholar

25. Araki T, Dahlberg SE, Hida T, Lydon CA, Rabin MS, Hatabu H, et al. Interstitial lung abnormality in stage IV non-small cell lung cancer: a validation study for the association with poor clinical outcome. Eur J Radiol Open 2019; 6: 128–31. doi: 10.1016/j.ejro.2019.03.003 ArakiT DahlbergSE HidaT LydonCA RabinMS HatabuH Interstitial lung abnormality in stage IV non-small cell lung cancer: a validation study for the association with poor clinical outcome Eur J Radiol Open 2019 6 128 31 10.1016/j.ejro.2019.03.003 Open DOISearch in Google Scholar

26. Kashihara T, Nakayama Y, Okuma K, Takahashi A, Kaneda T, Katagiri M, et al. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer. Radiother Oncol 2023; 180: 109454. doi: 10.1016/j.radonc.2022.109454 KashiharaT NakayamaY OkumaK TakahashiA KanedaT KatagiriM Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer Radiother Oncol 2023 180 109454 10.1016/j.radonc.2022.109454 Open DOISearch in Google Scholar